Literature DB >> 26713279

Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients.

Lucas Minig1, Cristina Zorrero1, Pablo Padilla Iserte1, Andres Poveda1.   

Abstract

Although it is assumed that the combination of chemotherapy and radical surgery should be indicated in all newly diagnosed advanced-stage ovarian cancer patients, one of the main raised questions is how to select the best strategy of initial treatment in this group of patients, neoadjuvant chemotherapy followed by interval debulking surgery or primary debulking surgery followed by adjuvant chemotherapy. The selection criteria to offer one strategy over the other as well as a stepwise patient selection for initial treatment are described. Selecting the best strategy of treatment in newly diagnosed advanced stage ovarian cancer patients is a multifactorial and multidisciplinary decision. Several factors should be taken into consideration: (1) the disease factor, related to the extension and localization of the disease as well as tumor biology; (2) the patient factor, associated with patient age, poor performance status, and co-morbidities; and (3) institutional infrastructure factor, related to the lack of prolonged operative time, an appropriate surgical armamentarium, as well as well-equipped intensive care units with well-trained personnel.

Entities:  

Keywords:  Advanced stage; Neoadjuvant chemotherapy; Ovarian cancer; Patients’ selection; Primary debulking surgery

Year:  2015        PMID: 26713279      PMCID: PMC4686416          DOI: 10.5662/wjm.v5.i4.196

Source DB:  PubMed          Journal:  World J Methodol        ISSN: 2222-0682


  45 in total

Review 1.  The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review.

Authors:  Flora Vernooij; Peter Heintz; Els Witteveen; Yolanda van der Graaf
Journal:  Gynecol Oncol       Date:  2007-04-12       Impact factor: 5.482

2.  Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.

Authors:  Mirjam J A Engelen; Henrike E Kos; Pax H B Willemse; Jan G Aalders; Elisabeth G E de Vries; Michael Schaapveld; Renee Otter; Ate G J van der Zee
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

3.  Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.

Authors:  I Vergote; I De Wever; W Tjalma; M Van Gramberen; J Decloedt; P van Dam
Journal:  Gynecol Oncol       Date:  1998-12       Impact factor: 5.482

4.  Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Tom Ehlen; Nick S Reed; Antonio Casado
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

5.  Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients.

Authors:  E J Junor; D J Hole; L McNulty; M Mason; J Young
Journal:  Br J Obstet Gynaecol       Date:  1999-11

6.  A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.

Authors:  R E Bristow; L R Duska; N C Lambrou; E K Fishman; M J O'Neill; E L Trimble; F J Montz
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

Review 7.  The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer.

Authors:  J Huober; A Meyer; U Wagner; D Wallwiener
Journal:  J Cancer Res Clin Oncol       Date:  2002-01-29       Impact factor: 4.553

8.  The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Authors:  Oliver Zivanovic; Eric L Eisenhauer; Qin Zhou; Alexia Iasonos; Paul Sabbatini; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2007-11-13       Impact factor: 5.482

9.  The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma.

Authors:  Sean C Dowdy; Sally A Mullany; Kathy R Brandt; Bonnie J Huppert; William A Cliby
Journal:  Cancer       Date:  2004-07-15       Impact factor: 6.860

10.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

View more
  5 in total

1.  The outcomes of intestinal resection during debulking surgery for ovarian cancer.

Authors:  Serdar Gökay Terzioğlu; Murat Özgür Kılıç; Nilüfer Çetinkaya; Eralp Baser; Tayfun Güngör; Cevdet Adıgüzel
Journal:  Turk J Surg       Date:  2017-06-01

2.  Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.

Authors:  Lijuan Yang; Bo Zhang; Guangyang Xing; Jingran Du; Bin Yang; Qianqian Yuan; Yongxiu Yang
Journal:  PLoS One       Date:  2017-10-23       Impact factor: 3.240

3.  Preoperative colonoscopy in patients with a supposed primary ovarian cancer.

Authors:  Renata Raś; Edyta Barnaś; Joanna Skręt- Magierło; Anna Drozdzowska; Ewelina Bartosiewicz; Marek Sobolewski; Andrzej Skręt; Krzysztof Gutkowski
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

4.  Minimally invasive repair of a left diaphragm hernia after debulking surgery for advanced ovarian cancer.

Authors:  Sarah Ehmann; Bernard Park; Dennis S Chi
Journal:  Gynecol Oncol Rep       Date:  2021-02-11

5.  Diaphragm hernia after debulking surgery in patients with ovarian cancer.

Authors:  Sarah Ehmann; Emeline M Aviki; Yukio Sonoda; Thomas Boerner; Dib Sassine; David R Jones; Bernard Park; Murray Cohen; Norman G Rosenblum; Dennis S Chi
Journal:  Gynecol Oncol Rep       Date:  2021-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.